Theorem Clinical Research


Novo Nordisk, Takeda, Servier, Celgene among top sponsors rated by investigative sites in new CenterWatch survey

Monday, March 2, 2015 08:00 AM

More than 1,900 global investigative sites rate the best biopharmaceutical companies with which to work in a new survey conducted by CenterWatch, a leading provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.

More... »

Quest Diagnostics

Orca Pharmaceuticals, AstraZeneca partner to treat autoimmune disease

Wednesday, February 25, 2015 11:23 AM

Orca Pharmaceuticals, a U.K. based biopharmaceutical company, and AstraZeneca have announced a three-year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (RORγ). Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there currently is no safe, orally available and effective treatment.

More... »

MedImmune, NIST partner to advance development of biological therapies

Monday, February 23, 2015 01:06 PM

MedImmune, the global biologics R&D arm of AstraZeneca, and the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) have signed a five-year agreement to jointly support research that will help advance drug discovery and manufacturing. The effort will focus on tools and measurements that will be used in the development and production of biopharmaceuticals, which are drugs and treatments derived from biological, rather than chemical, sources.

More... »

PharmaTimes clinical research awards to be presented Feb. 26

Thursday, February 12, 2015 03:33 PM

The 2015’s PharmaTimes Clinical Researcher of the Year—The Americas awards will be presented Feb. 26 in North Carolina.

More... »

COMBACTE-MAGNET launched to revitalize antibiotic development

Wednesday, February 4, 2015 01:41 PM

Thirty-three European academic partners and five pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the Innovative Medicines Initiative (IMI) antimicrobial resistance research program New Drugs 4 Bad Bugs (ND4BB).

More... »

AstraZeneca, MD Anderson collaborate for ovarian/gynecologic cancers

Monday, February 2, 2015 01:50 PM

AstraZeneca and the University of Texas MD Anderson Cancer Center have announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

More... »

AstraZeneca collaborates to use CRISPR technology

Friday, January 30, 2015 12:27 PM

AstraZeneca has announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas. The four research collaborations are with the Wellcome Trust Sanger Institute, Cambridge, U.K.; the Innovative Genomics Initiative, California; Thermo Fisher Scientific, Waltham, Mass.; and the Broad Institute/Whitehead Institute, Cambridge, Mass. The technology will allow AZ to identify and validate new drug targets in preclinical models that closely resemble human disease.

More... »

Astellas Pharma hires global executive Eric Terhaerdt

Friday, January 16, 2015 10:11 AM

Eric Terhaerdt has been named senior vice president of Global Development Operations for Astellas Pharma, based in Tokyo, Japan. Terhaerdt will be located at Astellas' headquarters for the Americas in Northbrook, Ill., and will report to Dr. Bernie Zeiher, executive vice president, Global Development and Therapeutic Area head: immunology, infectious disease, transplantation and central nervous system and pain, with Astellas Pharma Global Development.

More... »

Moderna, Merck to develop messenger RNA-based antiviral vaccines

Wednesday, January 14, 2015 12:41 PM

Moderna Therapeutics has announced a license and collaboration agreement with Merck, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). Moderna’s work in the collaboration will be led by Valera, its venture focused on the development of mRNA vaccines and therapeutics to fight infectious disease. Moderna is privately held, Cambridge, Mass.-based company founded by Flagship VentureLabs.

More... »

Tetragenetics, MedImmune collaborate on ion channel drug discovery program

Thursday, January 8, 2015 01:03 PM

Tetragenetics, an emerging biotechnology company based in Cambridge, Mass., will collaborate with MedImmune, the global biologics R&D arm of AstraZeneca, on antibody drug discovery research. Specifically, Tetragenetics will use its proprietary ion channel production technology, SionX, to produce up to five ion channel antigens for MedImmune's antibody drug discovery programs.

More... »


March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs